Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463254 | 1.00 | UGT2B7 (0.63) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL29350727 | 1.00 | UGT2B7 (0.63) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL29471009 | 1.00 | UGT2B7 (0.63) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL307143 | 1.00 | UGT2B7 (0.63) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL14019306 | 1.00 | UGT2B7 (0.63) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL25434816 | 1.00 | UGT2B7 (0.63) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL38429 | 1.00 | UGT2B7 (0.63) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| Hydrochloric Acid SCHEMBL6417289 | 0.98 | UGT2B7 (0.61) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| Ammonia Solution, Strong SCHEMBL27895021 | 0.98 | UGT2B7 (0.61) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL29254013 | 0.93 | UGT2B7 (0.55) | UGT2B7HTR2AHTR2CHTR2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | LUPIN LIMITED (IN) | 2025-07-01 | — | — | US | claimed |
| US-12075637-B2 | Perovskite solar cell and fabrication method thereof | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2024-08-27 | — | — | US | claimed |
| CN-114981253-B | Process and intermediates for preparing chroman compounds and methods therefor | 印度鲁宾有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-118084786-A | Schiff base compound, preparation method and application thereof | 安徽省东超科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117859209-A | Perovskite solar cell and preparation method thereof | 宁德时代新能源科技股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| EP-4300602-A1 | PEROVSKITE SOLAR CELL AND PREPARATION METHOD THEREFOR | Contemporary Amperex Technology Co., Limited (CN) | 2024-01-03 | — | — | EP | claimed |
| US-20230403869-A1 | PEROVSKITE SOLAR CELL AND FABRICATION METHOD THEREOF | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2023-12-14 | — | — | US | claimed |
| WO-2023216132-A1 | PEROVSKITE SOLAR CELL AND PREPARATION METHOD THEREFOR | 宁德时代新能源科技股份有限公司 | 2023-11-16 | — | — | WO | claimed |
| WO-2023214011-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | ENZYMICALS AG (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4273254-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | Enzymicals AG (DE) | 2023-11-08 | — | — | EP | claimed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | claimed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | claimed |
| US-20020193636-A1 | Benzaldehyde reacted with a primary amine to give an imine, which is hydrogenated with hydrogen in the presence of a catalyst and a water miscible solvent | BASF AKTIENGESELLCHAFT (DE) | 2002-12-19 | — | — | US | claimed |
| US-6476268-B1 | Preparation of N-benzylamines | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | claimed |
| EP-1247799-A2 | Process for the preparation of N-benzylamines | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-09 | — | — | EP | claimed |
| EP-0731790-A1 | TACHYKININ ANTAGONISTS | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1996-09-18 | — | — | EP | claimed |
| EP-0508307-B1 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL CO (JP) | 1995-11-29 | — | — | EP | claimed |
| EP-0508307-A2 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-14 | — | — | EP | claimed |
| US-5053512-A | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives | RESEARCH TRIANGLE INSTITUTE (US) | 1991-10-01 | — | — | US | claimed |
| US-4014895-A | Method for synthesis of optically active thiolactones | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | UGT2B7 2187/4885HTR2A 1014/4885HTR2C 547/4885 |
| US-20020193636-A1 | Benzaldehyde reacted with a primary amine to give an imine, which is hydrogenated with hydrogen in the presence of a catalyst and a water miscible solvent | HNMT, INMT, H1-2 | UGT2B7 2913/4885HTR2A 565/4885HTR2C 562/4885 |
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | CASR, CALCR, RYR1 | UGT2B7 1002/4885HTR2A 239/4885HTR2C 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.